drugset
drugset / Trial / NCT06010342

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

NCT06010342 ↗

Phase 2 Recruiting 60 enrolled Teligene US
NaSingle-groupOpen-labelTreatment

Summary

The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions

Timeline

Start
2023-03-16
Primary completion
2027-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TL-118 Unknown 252 mg Oral

Indications

cancer